Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02954991 · ClinicalTrials.gov registry record · Phase 2
Phase 2 Study of Glesatinib, Sitravatinib or Mocetinostat in Combination With Nivolumab in Non-Small Cell Lung Cancer
A Phase 2 study, sponsored by Mirati Therapeutics.
- Terminated
- Registry status
- Phase 2
- Development phase
- 161
- Enrollment target
NCT02954991 is a Phase 2 study that was terminated before completion, run by Mirati Therapeutics. The registered enrollment target is 161 participants.
The verdict
NCT02954991, a Phase 2 study, was terminated before completion, sponsored by Mirati Therapeutics.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 161 participants
- Enrollment target
Study Summary
The study will evaluate the clinical activity of nivolumab in combination with 3 separate investigational agents, glesatinib, sitravatinib, or mocetinostat.
Interventions
- DRUG Nivolumab
- DRUG Mocetinostat
- DRUG Sitravatinib
- DRUG Glesatinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 161 participants |
| Start Date | 2016-11-07 |
| Est. Completion | 2021-11-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02954991
The ClinicalTrials.gov registry entry for NCT02954991 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 161 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mirati Therapeutics, which has 49 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Nivolumab is the first listed.
NCT02954991 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02954991 about?
NCT02954991 is a clinical study titled "Phase 2 Study of Glesatinib, Sitravatinib or Mocetinostat in Combination With Nivolumab in Non-Small Cell Lung Cancer". The study will evaluate the clinical activity of nivolumab in combination with 3 separate investigational agents, glesatinib, sitravatinib, or mocetinostat.
What is the current status of trial NCT02954991?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 161 participants. The study started on 2016-11-07. Estimated completion is 2021-11-04.
What interventions are being tested in trial NCT02954991?
The interventions under investigation include: Nivolumab (DRUG), Mocetinostat (DRUG), Sitravatinib (DRUG), Glesatinib (DRUG).
Who is sponsoring clinical trial NCT02954991?
This trial is sponsored by Mirati Therapeutics, which has 49 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.